Lefty-A Activators
Lefty-A activators constitute a diverse group of chemical compounds that indirectly enhance its functional activity, primarily by modulating various signaling pathways that interact with or impact Lefty-A's role in inhibiting Nodal signaling. Compounds like Retinoic Acid exert their effect by influencing the expression of genes within the TGF-β pathway, of which Lefty-A is a crucial component, thus enhancing Lefty-A's inhibitory action on Nodal signaling. Similarly, Dorsomorphin, LDN-193189, and SB431542 function by inhibiting BMP signaling and TGF-β receptor kinases, respectively. These inhibitions shift the cellular signaling balance, allowing Lefty-A to more effectively exert its antagonistic effects on Nodal signaling, a pathway closely interlinked with BMP and TGF-β pathways. Furthermore, A-83-01 and LY364947, both TGF-β receptor kinase inhibitors, and PD173074, an FGFR inhibitor, contribute to this enhancement by reducing competitive signaling pathways, thereby potentiating Lefty-A's role in Nodal pathway inhibition.
The second set of activators, including CHIR99021, IWP-2, and BIO, modulate Wnt signaling, a pathway that indirectly influences Nodal signaling. By altering Wnt signaling dynamics, these compounds facilitate an environment conducive to Lefty-A's inhibitory action on Nodal signaling. CHIR99021, a GSK-3β inhibitor, and BIO, a GSK-3 inhibitor, specifically modulate Wnt/β-catenin signaling, thereby affecting Nodal pathway dynamics. Additionally, SB505124 and SIS3, which inhibit ALK4/5/7 and Smad3 respectively, also contribute to enhancing Lefty-A's activity. They do this by modulating TGF-β signaling, a pathway that when inhibited, permits Lefty-A to more effectively inhibit Nodal signaling. Collectively, these Lefty-A activators, through their targeted effects on various cellular signaling pathways, especially those intersecting with the Nodal pathway, facilitate an enhancement of Lefty-A's primary function of Nodal pathway inhibition, illustrating the complex interplay of cellular signaling in regulating protein function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid enhances Lefty-A activity by influencing cellular differentiation pathways. It modulates the expression of genes in the TGF-β pathway, which Lefty-A is a part of, leading to an indirect enhancement of Lefty-A's inhibitory role on Nodal signaling. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $182.00 $736.00 | 28 | |
Dorsomorphin indirectly enhances Lefty-A activity by inhibiting BMP signaling. This inhibition allows Lefty-A to more effectively exert its antagonistic effects on Nodal signaling, as BMP and Nodal pathways are interconnected. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor kinase inhibitor, indirectly enhances Lefty-A activity by reducing competitive TGF-β signaling, thereby allowing Lefty-A to be more effective in its inhibition of Nodal signaling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947, another TGF-β receptor kinase inhibitor, functions similarly to SB431542, indirectly enhancing Lefty-A activity by inhibiting TGF-β signaling and thus allowing Lefty-A to more effectively inhibit Nodal signaling. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A-83-01 inhibits TGF-β type I receptor ALK5, which indirectly enhances Lefty-A's activity by reducing signaling that competes with Lefty-A's inhibitory role in Nodal signaling. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 inhibits FGFR, which indirectly enhances Lefty-A activity. This is because FGFR signaling can modulate Nodal signaling, and inhibition of FGFR allows Lefty-A to more effectively inhibit Nodal signaling. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 inhibits BMP type I receptors ALK2/3/6, which indirectly enhances Lefty-A activity. By inhibiting BMP signaling, it allows Lefty-A to exert its inhibitory effects on Nodal signaling more effectively. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR99021 is a GSK-3β inhibitor that indirectly enhances Lefty-A activity by modulating Wnt signaling. Alterations in Wnt signaling can affect Nodal signaling, thus indirectly enhancing Lefty-A's inhibitory role. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt production, which can indirectly enhance Lefty-A activity. By reducing Wnt signaling, IWP-2 can influence Nodal signaling pathways, where Lefty-A acts as an inhibitor. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
BIO is a GSK-3 inhibitor, which indirectly enhances Lefty-A activity by modulating Wnt/β-catenin signaling. This modulation can affect Nodal signaling, indirectly enhancing Lefty-A's functional role. | ||||||